In this work, we test our hypothesis and analyze tumor tissues for MTAP expression status in correlation with clinical responses to pemetrexed in patients with metastatic UC who either enrolled on our phase II clinical trial (NCT02693717) or were historically treated with pemetrexed. This evidence concerns the gene MTAP and neoplasm.